6929 Stock Overview
An investment holding company, researches, develops, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People’s Republic of China, and the United States. More details
Snowflake Score | |
---|---|
Valuation | 6/6 |
Future Growth | 2/6 |
Past Performance | 5/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 6929 from our risk checks.
OrbusNeich Medical Group Holdings Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$3.83 |
52 Week High | HK$16.86 |
52 Week Low | HK$3.79 |
Beta | 0 |
11 Month Change | -23.40% |
3 Month Change | -33.28% |
1 Year Change | n/a |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -70.98% |
Recent News & Updates
Recent updates
Shareholder Returns
6929 | HK Medical Equipment | HK Market | |
---|---|---|---|
7D | -24.5% | -1.0% | -1.5% |
1Y | n/a | -35.3% | 13.6% |
Return vs Industry: Insufficient data to determine how 6929 performed against the Hong Kong Medical Equipment industry.
Return vs Market: Insufficient data to determine how 6929 performed against the Hong Kong Market.
Price Volatility
6929 volatility | |
---|---|
6929 Average Weekly Movement | 7.3% |
Medical Equipment Industry Average Movement | 9.9% |
Market Average Movement | 8.9% |
10% most volatile stocks in HK Market | 18.9% |
10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 6929's share price has been volatile over the past 3 months.
Volatility Over Time: 6929's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2001 | 954 | David Chien | orbusneich.com |
OrbusNeich Medical Group Holdings Limited, an investment holding company, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People’s Republic of China, and the United States. The company offers semi-compliant balloons and scoring balloons for pre-dilatation and lesion preparation, coronary stents for implantation, non-compliant balloons for post-dilatation, and specialty catheters. Its product portfolio covers various treatment processes in percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures.
OrbusNeich Medical Group Holdings Limited Fundamentals Summary
6929 fundamental statistics | |
---|---|
Market cap | HK$3.17b |
Earnings (TTM) | HK$278.81m |
Revenue (TTM) | HK$1.17b |
10.6x
P/E Ratio2.5x
P/S RatioIs 6929 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6929 income statement (TTM) | |
---|---|
Revenue | US$149.38m |
Cost of Revenue | US$46.37m |
Gross Profit | US$103.01m |
Other Expenses | US$67.38m |
Earnings | US$35.64m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Mar 07, 2024
Earnings per share (EPS) | 0.043 |
Gross Margin | 68.96% |
Net Profit Margin | 23.86% |
Debt/Equity Ratio | 0% |
How did 6929 perform over the long term?
See historical performance and comparison